Virax Biolabs Group (VRAX) Competitors $2.09 -0.09 (-4.13%) Closing price 04:00 PM EasternExtended Trading$2.20 +0.12 (+5.50%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends VRAX vs. CGTX, CVM, INKT, KALA, MRNS, UBX, DARE, VRCA, MTEX, and CVKDShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Cognition Therapeutics (CGTX), CEL-SCI (CVM), MiNK Therapeutics (INKT), KALA BIO (KALA), Marinus Pharmaceuticals (MRNS), Unity Biotechnology (UBX), Daré Bioscience (DARE), Verrica Pharmaceuticals (VRCA), Mannatech (MTEX), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Cognition Therapeutics CEL-SCI MiNK Therapeutics KALA BIO Marinus Pharmaceuticals Unity Biotechnology Daré Bioscience Verrica Pharmaceuticals Mannatech Cadrenal Therapeutics Cognition Therapeutics (NASDAQ:CGTX) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations. Is CGTX or VRAX more profitable? Virax Biolabs Group's return on equity of 0.00% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -150.93% -100.82% Virax Biolabs Group N/A N/A N/A Does the MarketBeat Community believe in CGTX or VRAX? Cognition Therapeutics received 20 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. CompanyUnderperformOutperformCognition TherapeuticsOutperform Votes2068.97% Underperform Votes931.03% Virax Biolabs GroupN/AN/A Which has more risk & volatility, CGTX or VRAX? Cognition Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Which has better earnings and valuation, CGTX or VRAX? Virax Biolabs Group has higher revenue and earnings than Cognition Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$25.79M-$0.97-0.74Virax Biolabs Group$160K42.37-$6.73MN/AN/A Does the media prefer CGTX or VRAX? In the previous week, Cognition Therapeutics had 2 more articles in the media than Virax Biolabs Group. MarketBeat recorded 2 mentions for Cognition Therapeutics and 0 mentions for Virax Biolabs Group. Cognition Therapeutics' average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score. Company Overall Sentiment Cognition Therapeutics Neutral Virax Biolabs Group Neutral Do institutionals and insiders believe in CGTX or VRAX? 43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 20.8% of Cognition Therapeutics shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate CGTX or VRAX? Cognition Therapeutics presently has a consensus target price of $8.30, indicating a potential upside of 1,059.22%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cognition Therapeutics is more favorable than Virax Biolabs Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCognition Therapeutics and Virax Biolabs Group tied by winning 6 of the 12 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.71M$2.23B$5.38B$9.11BDividend YieldN/A0.66%5.37%4.00%P/E RatioN/A5.1087.8117.51Price / Sales42.3787.411,285.9980.25Price / CashN/A16.2336.6032.90Price / Book1.053.374.944.66Net Income-$6.73M$29.98M$117.96M$224.69M7 Day Performance-8.34%0.34%2.29%3.11%1 Month Performance19.94%-1.74%3.26%5.17%1 Year Performance99.90%-16.60%27.03%22.24% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group0.2557 of 5 stars$2.09-4.1%N/A+107.6%$6.75M$160,000.000.005Gap UpCGTXCognition Therapeutics2.5501 of 5 stars$0.74-2.7%$8.30+1,021.5%-70.4%$30.75MN/A-0.7620CVMCEL-SCIN/A$0.41-2.4%N/A-83.4%$30.70MN/A-0.7243INKTMiNK Therapeutics2.4692 of 5 stars$0.77+5.9%$6.50+739.9%+0.0%$30.67MN/A-1.9830KALAKALA BIO4.0318 of 5 stars$6.55-3.8%$15.00+129.0%-2.3%$30.20M$3.89M-0.5330MRNSMarinus Pharmaceuticals4.6261 of 5 stars$0.54+0.8%$4.79+784.4%-94.4%$29.88M$31.47M-0.22110Analyst ForecastUBXUnity Biotechnology4.4593 of 5 stars$1.72-3.9%$7.33+326.4%+3.6%$28.98M$240,000.00-1.3160DAREDaré Bioscience1.2579 of 5 stars$3.33+6.7%$24.00+620.7%-10.2%$28.97M$1.88M-5.6430News CoverageNegative NewsVRCAVerrica Pharmaceuticals4.2255 of 5 stars$0.64-3.8%$9.50+1,396.1%-88.5%$28.96M$9.21M-0.3540News CoverageGap UpMTEXMannatech0.2554 of 5 stars$15.17+1.3%N/A+33.6%$28.60M$121.55M-18.73250Analyst ForecastGap UpCVKDCadrenal Therapeutics2.4278 of 5 stars$15.99-1.7%$32.00+100.1%N/A$28.51MN/A-2.394Positive News Related Companies and Tools Related Companies Cognition Therapeutics Competitors CEL-SCI Competitors MiNK Therapeutics Competitors KALA BIO Competitors Marinus Pharmaceuticals Competitors Unity Biotechnology Competitors Daré Bioscience Competitors Verrica Pharmaceuticals Competitors Mannatech Competitors Cadrenal Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRAX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
